3396
antibody from Cell Signaling Technology, Inc
Targeting: ZEB1
AREB6, BZP, FECD6, NIL-2-A, PPCD3, TCF8, ZEB, Zfhep, Zfhx1a
Antibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 3396 - Provider product page
- Provider
- Cell Signaling Technology, Inc
- Proper citation
- Cell Signaling Technology Cat#3396, RRID:AB_1904164
- Product name
- ZEB1 (D80D3) Rabbit mAb
- Antibody type
- Monoclonal
- Reactivity
- Human
- Host
- Rabbit
- Storage
- -20°C
Submitted references Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.
Acquired expression of NFATc1 downregulates E-cadherin and promotes cancer cell invasion.
SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation.
Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
Stabilization of phenotypic plasticity through mesenchymal-specific DNA hypermethylation in cancer cells.
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.
Marín-Aguilera M, Codony-Servat J, Reig Ò, Lozano JJ, Fernández PL, Pereira MV, Jiménez N, Donovan M, Puig P, Mengual L, Bermudo R, Font A, Gallardo E, Ribal MJ, Alcaraz A, Gascón P, Mellado B
Molecular cancer therapeutics 2014 May;13(5):1270-84
Molecular cancer therapeutics 2014 May;13(5):1270-84
MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.
Rajabi H, Alam M, Takahashi H, Kharbanda A, Guha M, Ahmad R, Kufe D
Oncogene 2014 Mar 27;33(13):1680-9
Oncogene 2014 Mar 27;33(13):1680-9
Acquired expression of NFATc1 downregulates E-cadherin and promotes cancer cell invasion.
Oikawa T, Nakamura A, Onishi N, Yamada T, Matsuo K, Saya H
Cancer research 2013 Aug 15;73(16):5100-9
Cancer research 2013 Aug 15;73(16):5100-9
SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation.
Ono H, Imoto I, Kozaki K, Tsuda H, Matsui T, Kurasawa Y, Muramatsu T, Sugihara K, Inazawa J
Oncogene 2012 Nov 22;31(47):4923-34
Oncogene 2012 Nov 22;31(47):4923-34
Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L
Cancer research 2012 Jan 15;72(2):527-36
Cancer research 2012 Jan 15;72(2):527-36
Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
Grassian AR, Lin F, Barrett R, Liu Y, Jiang W, Korpal M, Astley H, Gitterman D, Henley T, Howes R, Levell J, Korn JM, Pagliarini R
The Journal of biological chemistry 2012 Dec 7;287(50):42180-94
The Journal of biological chemistry 2012 Dec 7;287(50):42180-94
Stabilization of phenotypic plasticity through mesenchymal-specific DNA hypermethylation in cancer cells.
Kurasawa Y, Kozaki K, Pimkhaokham A, Muramatsu T, Ono H, Ishihara T, Uzawa N, Imoto I, Amagasa T, Inazawa J
Oncogene 2012 Apr 12;31(15):1963-74
Oncogene 2012 Apr 12;31(15):1963-74
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.
Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, Liu M, Chen CT, Yu D, Hung MC
Nature cell biology 2011 Mar;13(3):317-23
Nature cell biology 2011 Mar;13(3):317-23
No comments: Submit comment
No validations: Submit validation data